ACCUSTEM SCIENCES INC (ACUT:OTCMKTS)
$0.265 -0.015 (-5.3571%)
Analysed ACCUSTEM SCIENCES INC (ACUT:OTCMKTS) News Sources
AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP)
08-01-2026
yahoo.com
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
18-09-2025
yahoo.com
AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning
17-09-2025
yahoo.com
Life Science Virtual Investor Forum Agenda Announced for September 18th
16-09-2025
yahoo.com
AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th
16-09-2025
yahoo.com
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
16-06-2025
yahoo.com
AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening
28-04-2025
yahoo.com
AccuStem Sciences, Inc. Signs Agreement to Access Blood Samples from Lung Cancer Screening Trial to Expedite MSC Commercialization Plan
16-04-2025
yahoo.com
What is the current price of ACCUSTEM SCIENCES INC (ACUT:OTCMKTS)?
The current price of ACCUSTEM SCIENCES INC (ACUT:OTCMKTS) is $0.265.
ACCUSTEM SCIENCES INC (ACUT:OTCMKTS) absolute price change since previous trading day?
The absolute price change of ACCUSTEM SCIENCES INC (ACUT:OTCMKTS) since the previous trading day is $-0.015.
ACCUSTEM SCIENCES INC (ACUT:OTCMKTS) percentage price change since previous trading day?
The percentage price change of ACCUSTEM SCIENCES INC (ACUT:OTCMKTS) since the previous trading day is -5.3571%.
What is the most recent average sentiment score for ACCUSTEM SCIENCES INC (ACUT:OTCMKTS)?
The most recent average sentiment score for ACCUSTEM SCIENCES INC (ACUT:OTCMKTS) is 80 out of 100.
What is the most recent average sentiment for ACCUSTEM SCIENCES INC (ACUT:OTCMKTS)?
The most recent sentiment for ACCUSTEM SCIENCES INC (ACUT:OTCMKTS) is .
SEC-8K** Filing Available For ACCUSTEM SCIENCES INC (ACUT:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.